

OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.

ENT OF COMMERCE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginis 22313-1450 www.uspto.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/725,451

1940 DUKE STREET

ALEXANDRIA, VA 22314

22850

12/03/2003

Shingo Kakuo

246089US0

CONFIRMATION NO. 4055

FORMALITIES LETTER

OC000000012455273

Date Mailed: 04/27/2004

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.

 A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

■ For Rules Interpretation, call (703) 308-4216

■ To Purchase Patentin Software, call (703) 306-2600

■ For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



ALEXANDRIA, VIRGINIA 22313

ATTN: APPLICATION BRANCH

OBLON SPIVAK MCCLELIAND MAIER A NEUSTADT BC.

ATTORNEYS AT LAW

THIS IS A RESPONSE TO A NOTICE TO FILE MISSING PARTS OF AN APPLICATION

COMMISSIONER FOR PATENTS

Re: Inventor:

Shingo KAKUO, et al.

Serial No:

10/725,451

Filed:

December 3, 2003

For:

AROMATASE ACTIVATING AGENT

SIR:

Attached hereto for filing are the following papers:

Return Copy - Notice to File Missing Parts
Request for Extension of Time - One Month
Filing of Declaration Under 37 CFR 1.53(f)
Executed Declaration and Power of Attorney (4 pp.)
Request for Priority
Priority Document (1)

Preliminary Amendment and Statement w/attached Sequence Listing and Computer-Readable Form (CRF)

Our credit card payment form in the amount of \$110.00 is attached covering any required fees. In the event that any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 CFR 1.136 for the necessary extension of time. A duplicate of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Vincent K. Shier, Ph.D. Registration No. 50,552

Customer Number

246089US0

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Docket No.

Docker No. 246089US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN REAPPLICATION OF: Shingo KAKUO, et al.

TRASERIAL NO: 10/725,451

GAU:

1654

FILED:

December 3, 2003

EXAMINER:

FOR:

AROMATASE ACTIVATING AGENT

REQUEST FOR EXTENSION OF TIME UNDER 37 C.F.R. 1.136

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

it is necessive that a one month extension of time be granted to July 27, 2004 for	
	filing a response to the Official Action dated:
	responding to the requirements in the Notice of Allowability dated:
	filing the Formal Drawings. The Issue Fee due has been timely filed.
	responding to the Notice to File Missing Parts of Application dated: April 27, 2004
	filing a Notice of Appeal. A timely response to the final rejection, due has been filed.
	filing an Appeal Brief. A Notice of Appeal was filed on:
	Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown below is reduced by one-half.

The required fee of \$110.00 is enclosed herewith by credit card payment and any further charges may be made against the Attorney of Record's Deposit Account No. <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C. Norman F. Oblon

~

Vincent K. Shier, Ph.D. Registration No. 50,552

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03) Docket No. 246089US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Shingo KAKUO, et al.

ADEMAL HONDLIK.

L NUMBER: 10/725,451

ATTN: APPLICATION BRANCH

FILING DATE:

December 3, 2003

FOR:

AROMATASE ACTIVATING AGENT

FILING OF DECLARATION UNDER 37 CFR 1.53(f)

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Responsive to the notification dated April 27, 2004, and in accordance with the provisions of 37 CFR 1.53(f), Applicants submit herewith a Rule 63 Declaration.

The required fee was paid at the time of filing the application.

In light of the foregoing, this application is deemed to be in proper condition for examination and such favorable action is earnestly solicited.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Vincent K. Shier, Ph.D. Registration No. 50,552

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)